Prophylactic azithromycin therapy after lung transplantation: Post hoc analysis of a randomized controlled trial

American Journal of Transplantation

Volumn 16, Issue 1, 2016, Pages 254-261

  Ruttens, D ^a   Verleden, S E ^a   Vandermeulen, E ^a   Bellon, H ^a   Vanaudenaerde, B M ^a   Somers, J ^a,b   Schoonis, A ^a   Schaevers, V ^a   Van Raemdonck, D E ^a,b   Neyrinck, A ^a,b   Dupont, L J ^a   Yserbyt, J ^a   Verleden, G M ^a   Vos, R ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CHRONIC DISEASE; CHRONIC LUNG ALLOGRAFT DYSFUNCTION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXERCISE; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT FAILURE; HUMAN; LUNG DISEASE; LUNG FUNCTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETRANSPLANTATION; RETROSPECTIVE STUDY; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; BRONCHIOLITIS OBLITERANS; COHORT ANALYSIS; COMPLICATION; FORCED EXPIRATORY VOLUME; GRAFT REJECTION; GRAFT SURVIVAL; MICROBIOLOGY; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR; SYNDROME;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AZITHROMYCIN; BACTEREMIA; BRONCHIOLITIS OBLITERANS; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LUNG TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; SYNDROME; TRANSPLANTATION, HOMOLOGOUS;

EID: 84956955074     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13417     Document Type: Article

References (25)

1. Yusen RD, Edwards LB, Kucheryavaya AY, et al., The registry of the International Society for Heart and Lung Transplantation: Thirty-first adult lung and heart-lung transplant report-2014 focus theme: Retransplantation. J Heart Lung Transplant 2014; 33: 1009-1024.
2. Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P,. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant 2014; 33: 127-133.
3. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB,. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: Results of a pilot study. Am J Respir Crit Care Med 2003; 168: 121-125.
4. Verleden GM, Dupont LJ,. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 77: 1465-1467.
5. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE,. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174: 566-570.
6. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T,. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85: 36-41.
7. Vanaudenaerde BM, Meyts I, Vos R, et al., A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008; 832-843.
8. Vos R, Vanaudenaerde BM, Ottevaere A, et al., Long-term azithromycin therapy for bronchiolitis obliterans syndrome: Divide and conquer? J Heart Lung Transplant 2010; 29: 1358-1368.
9. Corris PA, Ryan VA, Small T,. et al. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax 2015; 70: 442-450.
10. Meyer KC, Raghu G, Verleden GM, et al., An international ISHLT/ATS/ERS clinical practice guideline: Diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J 2014; 44: 1479-1503.
11. Verleden SE, Ruttens D, Vandermeulen E, et al., Restrictive chronic lung allograft dysfunction: Where are we now? J Heart Lung Transplant 2015; 34: 625-630.
12. Sato M, Waddell TK, Wagnetz U, et al., Restrictive allograft syndrome (RAS): A novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011; 30: 735-742.
13. Vos R, Vanaudenaerde BM, Verleden SE, et al., A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 37: 164-172.
14. Troosters T, Gosselink R, Decramer M,. Six minute walking distance in healthy elderly subjects. Eur Respir J 1999; 14: 270-274.
15. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF,. Updating the minimal important difference for Six-Minute Walk Distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2010; 91: 221-225.
16. Vos R, Verleden SE, Ruttens D, et al., Azithromycin and the treatment of lymphocytic airway inflammation after lung transplantation. Am J Transplant 2014; 14: 2736-2748.
17. Vos R, Vanaudenaerde BM, Verleden SE, et al., Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation 2012; 94: 101-109.
18. Suhling H, Dettmer S, Rademacher J, et al., Spirometric obstructive lung function pattern early after lung transplantation. Transplantation 2012; 93: 230-235.
19. Suhling H, de Wall C, Rademacher J, et al., Low exercise tolerance correlates with reduced inspiratory capacity and respiratory muscle function in recipients with advanced chronic lung allograft dysfunction. Transplantation 2013; 95: 1045-1050.
20. Jain R, Hachem RR, Morrell MR, et al., Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010; 29: 531-537.
21. Li H, Liu D-H, Chen L-L, et al., Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother 2014; 58: 511-517.
22. Abo-Salem E, Fowler JC, Attari M, et al., Antibiotic-induced cardiac arrhythmias. Cardiovasc Ther 2014; 32: 19-25.
23. Giudicessi JR, Ackerman MJ,. Azithromycin and risk of sudden cardiac death: Guilty as charged or falsely accused? Cleve Clin J Med 2013; 80: 539-544.
24. Albert RK, Schuller JL,. COPD Clinical Research Network. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014; 189: 1173-1180.
25. Kapila A, Baz MA, Valentine VG, Bhorade SM,. AIRSAC investigators. Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: A survey. J Heart Lung Transplant 2015; 34: 65-74.